Blood

Vol. 146, Issue 1 Issue 1 2025
18
Articles

Articles in this Issue

Large-scale dependency and drug screens to characterize the therapeutic vulnerabilities of multiple myeloma with 1q+

Romanos Sklavenitis-Pistofidis, Elizabeth D. Lightbody, Mairead Reidy et al. Jul 03, 2025 pp. 89-103 10.1182/blood.2024025102

Abstract The development of targeted therapy for patients with multiple myeloma (MM) is hampered by the low frequency of actionable genetic abnormalities. Gain or amplification of ch...

Check the brakes on IRF4!

Charlotte Pawlyn Jul 03, 2025 pp. 8-9 10.1182/blood.2025028615

Interferon-γ sparks inflammatory fire in Castleman disease

Frits van Rhee, David Fajgenbaum Jul 03, 2025 pp. 5-7 10.1182/blood.2025029270

Are we ready for an MRD-driven approach in multiple myeloma?

Francesca Gay, Roberto Mina Jul 03, 2025 pp. 2-4 10.1182/blood.2024028273

Therapy-related juvenile myelomonocytic leukemia

Ahmed Mohamed, Aida I. Richardson Jul 03, 2025 pp. 127-127 10.1182/blood.2025028952

Isatuximab, carfilzomib, lenalidomide, and dexamethasone induction in newly diagnosed myeloma: analysis of the MIDAS trial

Aurore Perrot, Cyrille Touzeau, Jérôme Lambert et al. Jul 03, 2025 pp. 52-61 10.1182/blood.2024026230

Abstract For patients with transplant-eligible newly diagnosed multiple myeloma, induction therapy with a quadruplet regimen before autologous transplant is the standard of care. The...

How I treat Wiskott-Aldrich syndrome

Tanja C. Vallée, Michael H. Albert, Sung-Yun Pai Jul 03, 2025 pp. 41-51 10.1182/blood.2024026288

Abstract Wiskott-Aldrich syndrome (WAS) is a rare X-linked disorder, characterized by thrombocytopenia, eczema, recurrent infections, autoimmunity, and malignancy. Here, we discuss c...

A novel mouse model of hemoglobin SC disease reveals mechanisms underlying beneficial effects of hydroxyurea

Tahereh Setayesh, Mengna Chi, Zachery Oestreicher et al. Jul 03, 2025 pp. 13-28 10.1182/blood.2024028136

Abstract Sickle cell hemoglobin C (HbSC) disease results from compound heterozygosity of hemoglobin S (HbS) and hemoglobin C (HbC), comprising 30% of sickle cell disease (SCD). HbC i...

Metabolic pathways in deep vein thrombosis: a new frontier for therapeutic intervention

Ivan Budnik, Mariia Kumskova, Anil K. Chauhan Jul 03, 2025 pp. 29-40 10.1182/blood.2024027636

Abstract Venous thromboembolism, which includes deep vein thrombosis (DVT) and pulmonary embolism, is a common cardiovascular disorder associated with significant morbidity and morta...

HbSC gets its mouse model 75 years after discovery

Eduard J. van Beers Jul 03, 2025 pp. 1-2 10.1182/blood.2025029523

Another 1q bites the dust

Vikas A. Gupta, Lawrence H. Boise Jul 03, 2025 pp. 7-8 10.1182/blood.2025028903

Loss of BCL7A permits IRF4 transcriptional activity and cellular growth in multiple myeloma

Chandraditya Chakraborty, Srikanth Talluri, Moritz Binder et al. Jul 03, 2025 pp. 104-114 10.1182/blood.2024026588

Abstract Multiple myeloma (MM) is a complex hematological malignancy characterized by genomic changes and transcriptomic dysregulation. Initial exome sequencing approaches have faile...

IFN-γ promotes the progression of iMCD by activating inflammatory monocytes

Xuejiao Yin, Yi Liu, Shengnan Ding et al. Jul 03, 2025 pp. 76-88 10.1182/blood.2024027689

Abstract A deeper understanding of the immune landscape in patients with idiopathic multicentric Castleman disease (iMCD) is essential to establish early prognostic stratification an...

Tracking <i>clusterin</i> expression in hematopoietic stem cells reveals their heterogeneous composition across the life span

Shuhei Koide, Motohiko Oshima, Takahiro Kamiya et al. Jul 03, 2025 pp. 62-75 10.1182/blood.2024025776

Abstract Hematopoietic stem cells (HSCs) exhibit significant age-related phenotypic and functional alterations. Although single-cell technologies have elucidated age-related composit...

<i>Clusterin</i>(g) and decoding HSC aging

Alexander Gerbaulet Jul 03, 2025 pp. 4-5 10.1182/blood.2025029070

<i>DNMT3A</i> mutations are unlikely to affect interferon alfa treatment outcomes in patients with polycythemia vera

Ghaith Abu-Zeinah, Katie Erdos, Neville Lee et al. Jul 03, 2025 pp. 123-126 10.1182/blood.2024027528

Abstract DNMT3A mutations in patients with polycythemia vera were heterogeneous and not enriched in interferon alfa–treated patients. DNMT3A mutations had no detectable impact on the...

Cell-autonomous dysregulation of interferon signaling drives clonal expansion of <i>SRSF2</i>-mutant MDS stem/progenitor cells

Kouhei Takashima, Malgorzata Olszewska, Vrinda Jethalia et al. Jul 03, 2025 pp. 115-122 10.1182/blood.2024025670

Abstract Myelodysplastic syndromes (MDSs) are myeloid malignancies often driven by mutations in genes encoding splicing factors (SFs). How these mutations drive the clonal expansion...

<i>SRSF2</i>-mutated MDS: bortezomib STAT?

Aly Karsan Jul 03, 2025 pp. 9-11 10.1182/blood.2025029269

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page